Clinical Trials
11 trialsNCT06564844 2026-05-22
TROPION-Lung12
AstraZeneca
Phase 3 Active not recruiting
NCT06561685 2026-04-20
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT03664024 2024-08-22
KEYNOTE-782
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT02498860 2021-08-06
APICAL
Chonnam National University Hospital
Phase 2 Completed
NCT00949650 2018-04-06
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Boehringer Ingelheim
Phase 3 Completed
NCT02951637 2016-11-01
Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
Shanghai Chest Hospital
Phase 2 Unknown
NCT00940069 2016-02-22
TPEIAL
Hunan Province Tumor Hospital
Phase 2 Completed
NCT01565538 2014-09-15
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Sun Yat-sen University
Phase 2 Completed